🚀 Big News for Life Sciences and AI!

The U.S. Food and Drug Administration (FDA) has announced that all its centers will immediately begin deploying artificial intelligence (AI) internally, following the successful completion of a generative AI pilot program specifically designed for scientific reviewers.

Key details:
🌟Immediate deployment across all FDA centers has been ordered, with the goal of full integration by June 30, 2025.
🌟The generative AI tools are intended to help FDA scientists and subject-matter experts spend less time on tedious, repetitive tasks that often slow the review process for new therapies and products.
🌟FDA Commissioner Dr. Martin A. Makary highlighted the pilot’s success, noting that tasks that previously took days can now be performed in minutes, significantly accelerating the review timeline for new drugs and therapies.

We are excited for what the future holds and proud that Clinakos Inc.’s efforts in utilizing Integrated Patient Data™ and Medically Smart AI™ to speed up therapies being available to patients are aligned with these innovative developments at the US FDA’s initiatives.

👉Follow us at Clinakos Inc..

Read the Article here